Scientific Programme

Updated 1 June 2012

View the Interactive Conference Programme and create
your own conference schedule! Conference Session Planner

The Pre-Conference Programme and a list of Meetings
can be found here: Pre-Conference Programme and Meetings

Programme Overview 

Wednesday 6 June 
17:00-18:00  ECFS Annual General Meeting 
18:30-20:00 Opening Plenary
20:00-21:30  Welcome Reception 
Thursday 7 June 
07:15-08:15  Round Tables 
08:30-10:00  Symposium 1 - New Genetic Diagnostic and Prognostic Tools 
  Moderators: PF Pignatti (IT) / C. Férec (FR) 
  Impact of New Generation Sequencing  - H. Cuppens (BE) 
  CFTR2 ‘Going Live’ – G. Cutting (US) 
  In Silico Prediction Tools – J. Muller (FR) 
  Transcript Analysis in Diagnostics –  S. Gallati (CH) 
08:30-10:00  Symposium 2 - Where to next with the EU Registry? 
  Moderators: M. Macek (CZ) /  H. Olesen (DK) 
  Registry Data Improvement and Transparency – L. Viviani (IT) 
  Expanding Registry Recruitment - Reaching the Missing – V. Gulmans (NL) 
  Using Registries in Phase IV Drug Development - E. McKone (IE) 
  Benchmarking in the USA – M. Schechter (US) 
08:30-10:00 Symposium 3 - Reactive Airways Disease in CF
  Moderators: D. Murphy / K. Webb (UK) 
  How the CF Airway Smooth Muscle Reacts in Pro-inflammatory Conditions - J. Martin (CA) 
  Pharmacological and Clinical Basis of Airway Reactivity in CF - M. Fayon (FR) 
  Bronchodilating the Obstructed CF Airway: Which Interventions? – S. Elborn (UK) 
  Clinical Consequences of non-ABPA Atopy in CF – E. Kerem (IL) 
08:30-10:00  Symposium 4 - Exercise from Testing to Lifestyle 
  Moderators: H. Hebestreit (DE) / C. Reilly (IE)
  What Can We Learn from Exercise Testing – B. Arets (NL)
  Evidence Based Exercise Intervention – J. Bradley (UK)
  Exercise Implementation in Daily Life: A Patient Perspective – S. Clarke (UK)
  New Gadgets to Promote Physical Activity – L. Lands (CA)
08:30-10:00 Symposium 5 - Emotional Well-Being 
  Moderators: J. Abbott (UK) / L. Goldbeck (DE)
  Final TIDES: International Comparisons - A Quittner (US)
  Pharmacological Treatments for Mood Disorders -  M. Moran (IE)
  Psychological Management of Anxiety and Depression in Clinical Practice – T. Havermans (BE)
08:30-10:00  Symposium 6 - New Insights into the Microbiology of the CF Lung 
  Moderators. A. Oliver (ES) / M.Tunney (UK)
  The Molecular Microbiome of The Respiratory Tract – K. Bruce (UK)
  Long Term Evolution of Pathogens in CF – N. Cramer (DE)
  United Airways? – H. Krogh Johansen (DK)
  Impacts on Diagnosis and Treatment  - B. Tuemmler (DE)
10:00-10:30  Coffee Break 
10:30-12:00 Symposium 7 - Hot Topics in Neonatal Screening 
  Moderators:  B. Linnane (IE) / P. Farrell (US)
  Early Prophylaxis in Screened Neonates
Pro RSV: M. Schechter  (US)
Con RSV: K. Southern (UK)
Discussion
  PAP for Screening – O. Sommerburg (DE)
  2012 US Update – P. Farrell (US)
10:30-12:00 Symposium 8 - Difficult Nutritional Dilemmas 
  Mod.: H. Watson (UK) / S. Wolfe (UK)
  How Aggressive Should We Be in the Screened Patient? - A. Munck (FR)
  Management of the Ostomy Patient  - D. Kalnins (CA)
  Recurrent Acute Pancreatitis - M. Lowe  (US)
  Obese CF Patient - H. Mc Cabe (UK)
10:30-12:00  Symposium 9 - Mechanisms of Inflammation 
  Moderators: C. Taggart (UK) / M. Chanson (CH) 
  Overview of Innate Immunity – C. Taggart (UK)
  Interleukin 17 Pathways in CF Lung Disease – J. Davies (UK)
  Estrogen and Inflammation – C. Greene (IE)
  Connexins as anti-inflammatory targets in cystic fibrosis - M. Chanson (CH) 
10:30-12:00 Symposium 10 - Grand Rounds in Pulmonary Disease 
  Expert Panel: D. Bilton (UK) / K. De Boeck (BE) / H. Heijerman (NL) / I. Sermet (FR)
  Extracorporeal CO2 Removal in CF - is there a role? - D. Nazareth (UK)
  A Severe Febrile Illness in a CF Patient Following Steroid Treatment for ABPA. - A. Clayton (UK)
  Chronic Necrotising Pulmonary Aspergillosis in an Adult CF Patient. - A. Clayton (UK)
  Disseminated Scedosporium Apiospermum Infection in the Post-transplant Setting - C. Butler (AU)
  Acute Breathlessness in an Older Adult with CF and Recurrent Haemoptysis -W. Flight (UK)
  Humpty Dumpty had a great fall…. and developed Cystic Fibrosis? - F. Gilchrist (UK)
10:30-12:00  Symposium 11 - Long Term Consequences of Improved CF Care 
  Moderators: S. Bell (AU) / G. Taccetti (IT)
  Metabolic Complications of Ageing - B. Plant (IE)
  Dealing with Chronic Renal Failure – M. Walshaw (UK)
  Drug-induced Complications – D. Peckham (UK)
  It Is My Life – O. Tinsley (IE)
10:30-12:00  Symposium 12 - Novel Approaches to P. aeruginosa Target Identification, Validation and Inhibition 
  Moderators: M. Camara (UK) / G. Döring (DE)
  Animal models for drug development - L. Eberl (CH)
  New Targets from combined in vitro and animal screening of P. aeruginosa - M. Camara (UK) 
  POL7080, a novel antibiotic against Pseudomonas based on the Protein Epitope Mimetics Technology -K. Dembowsky (CH)
  P. aeruginosa Crystal Structures for Drug Optimisation – J. Naismith (UK)
12:00-15:00 Lunch 
12:30-14:00  Gilead Satellite Symposia - Programme
Gilead logo
12:30-14:00  Pharmaxis Satellite Symposia - Programme
Pharmaxis logo
14:00-15:00  Guided Poster Tours and Posters for Discussion (see Poster Information)
14:00-15:00  ePoster Corner Sessions (see Poster Information)
15:00-16:30  Workshop1 - CF below the Diaphragm
  Moderators: L. Hjelte (SE) / C. Taylor (UK) 
  WS1.1 - Liver Disease in Cystic Fibrosis – B. Bourke (IE) 
  WS1.2 - Rate of Decline in Serum Trypsinogen as a Validation for the PIP Score – K. Keenan (CA) 
  WS1.3 - Prevalence of Cystic Fibrosis Related Diabetes Unaffected by Steadily Improving Clinical Condition. A Danish Retrospective Birth Cohort. – K. Knudsen (DK) 
  WS1.4 - The glucose metabolism in CFRD : comparing the different methods for screening CFRD – C. Mainguy (FR) 
  WS1.5 - The Use of Bedside Ultrasonography to Identify Delayed Gastric Emptying in Cystic Fibrosis – D. Nazareth (UK) 
  WS1.6 - The Need Of An Appropriate Diagnosis Of Gastroesophageal Reflux Disease In Cystic Fibrosis Patients: Impact On Clinical Management – F. Alghisi (IT) 
  WS1.7 - Gastroesophageal reflux in adult cystic fibrosis: a primary phenomenon or secondary to respiratory dysfunction? – A. Pauwels (BE) 
  WS1.8  - Risks of PPI treatment in patients with cystic fibrosis: effect of gastric juice of patients “on” PPI on IL-8 production by CF primary bronchial epithelial cells. – A. Pauwels (BE) 
15:00-16:30   Workshop 2 - Controlling Epithelial Inflammation
  Moderators: P. McCray (US) / JM Sallenave (FR) 
  WS2.1 - Investigation of MiRNA Regulation of ER Stress in Cystic Fibrosis Airway Epithelium – I. Oglesby (IE) 
  WS2.2 - Partially degraded N-terminal half delF508 CFTR molecule produces aggregation rearrangement of intermediate filaments in fully differentiated human bronchial epithelium - K. Du (CA) 
  WS2.3 - Pseudomonas aeruginosa Enhanced Gap Junctional Communication by a TLR5 and MAPK-Dependent Mechanism in Airway Epithelial Cells – D. Losa (CH) 
  WS2.4 - Cx26 regulates Klf Gene Expression and Proliferation of Human Airway Epithelial Cells Undergoing Repair – M. Chanson (CH) 
  WS2.5 - Airway epithelial regeneration is abnormal in CF in absence of endogenous infection and inflammation – D. Adam (FR) 
  WS2.6 - Potassium Channel Currents Induced by Lipoxin Stimulate Airway Epithelial Repair – P. Buchanan (IE) 
  WS2.7 - Rapid Effect of 17?-Estradiol on Airway Surface Liquid Hydration of Normal and Cystic Fibrosis Epithelia – V. Saint-Criq (IE) 
  WS2.8 - Slc26a9-mediated Cl- secretion is enhanced in allergic airway inflammation and prevents mucus obstruction in mouse airways – P. Anagnostopoulou (DE) 
  WS2.9 - Expression and regulation of IFRD1 in neutrophils of cystic fibrosis patients – A. Hector (DE) 
15:00-16:30   Workshop 3 - Changing Epidemiology and Outcomes
  Moderators:  M. Schechter (US) / D. Taylor-Robinson (UK) 
  WS3.1 - Changing incidence of CF in Ireland? – P. Mayne (IE) 
  WS3.2 - Who is reported in the Belgian, Dutch and French CF registries? – M. Thomas (BE) 
  WS3.3 - Longitudinal Changes in Lung Function and Risk of Death in Cystic Fibrosis: Developing a Joint Model for the UK Population – D. Taylor-Robinson (UK) 
  WS3.4 - Determinants of Lung Disease Progression in Children with CF – P. Farrell (US) 
  WS3.5 - Patients Diagnosed with CF in Adulthood; Clinical Course Following Diagnosis and Treatment at a Regional UK Centre – C. Etherington (UK) 
  WS3.6 - The CF-ABLE Score: A Novel Clinical Prediction Tool in Cystic Fibrosis – C. McCarthy (IE) 
  WS3.7 - Survival at low lung function in cystic fibrosis: cohort study from 1995 to 2010 – M. Osman (UK) 
  WS3.8 - The effect of socioeconomic deprivation on clinical outcomes in Cystic Fibrosis – I. Doull (UK) 
  WS3.9 - How much importance should we attribute to socioeconomic status in families with patients with CF? – P. Lambrecht (BE) 
15:00-16:30   Workshop 4 - Adherence 2012
  Moderators:  K. Russo (UK) / V. Bregnballe (DK) 
  WS4.1 - Clinical Supervision Improves Treatment Fidelity to an Adherence Intervention – A. Alpern (US) 
  WS4.2 - CF Patients’ beliefs about nebuliser treatment: implications for adherence to treatment – R. Mills (UK) 
  WS4.3 - Barriers to adherence in cystic fibrosis: the perspectives of young patients and their parents – V. Bregnballe (DK) 
  WS4.4 - The Effect of Remote Monitoring and Third Party Intervention on Adherence with Inhaled Therapies in Patients with Cystic Fibrosis Using the I-neb Insight Online Patient Management System. –  D. Peckham (UK) 
  WS4.5 - Knowledge and Skills in Managing CF: Data from the I Change Adherence and Raise Expectations (iCARE) Study – A. Quittner (US) 
  WS4.6 - The Psychometric Properties of CF-Specific Measures of Health Beliefs and Motivation to Adhere – K. Riekert (US) 
15:00-16:30   Workshop 5 - Clearing Infections from Airways
  Moderators: T. Lee (UK) / L. Dupont (BE) 
  WS5.1 - Inhaled glutathione in cystic fibrosis – M. Griese (DE) 
  WS5.2 - Inhaled Dry Powder Mannitol in Cystic Fibrosis (CF): Impact on Pulmonary Exacerbations (PEs) in the Phase III Studies (CF-301 & CF-302) – D. Bilton (UK) 
  WS5.3 - Wide Pharmacokinetic Variability Of Ciprofloxacin In Patients With Cystic Fibrosis (CF) – A Reason Of Treatment Failure? – C. Dalboege (DK) 
  WS5.4 - Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients with Chronic Burkholderia Species (BURK) Infection: Final Results from a Randomized, Placebo-Controlled Trial – E. Tullis (CA) 
  WS5.5 - A randomised, open label phase 3 study to evaluate the efficacy and safety of a dry powder formulation of inhaled colistimethate sodium (Colobreathe®) versus tobramycin nebuliser solution (TNS) in cystic fibrosis subjects with chronic Pseudomonas aerugino – M. Goldman (UK) 
  WS5.6 - A Challenging Double-Blind, Placebo-Controlled Study of Tobramycin Inhalation Powder in Cystic Fibrosis: Results of the EDIT Trial – M. Higgins (UK) 
15:00-16:30  Workshop 6 - New Therapies Targeting Basic Defects
  Moderators: M. Boyle (US)  / M. Ballmann (DE)
  Overview – M. Boyle (US) 
  WS6.2 - Anti-inflammatory pulmonal therapy of CF-patients with Amitriptyline and Placebo - a randomised, double-blind, placebo-controlled phase IIb multicenter, cohort-study – C. Adams (DE) 
  WS6.3 - Measures of Nutritional Status in Two Phase 3 Trials of Ivacaftor in Subjects with Cystic Fibrosis Who Have the G551D-CFTR Mutation – D. Borowitz (US) 
  WS6.4 - Long-Term Safety and Efficacy of Ivacaftor in Subjects with Cystic Fibrosis Who Have the G551D-CFTR Mutation – E. McKone (IE) 
  WS6.5 - Ivacaftor in Subjects 6 to 11 Years of Age with Cystic Fibrosis and the G551D-CFTR Mutation – J. Davies (UK) 
16:30-17:00 Coffee Break 
17:00-18:30  Workshop 7 - Lung Clearance Index in Real Life
  Moderators: J. Davies (UK) / M. Gappa (DE) 
  WS7.2 - Lung Clearance Index: Comparison of Helium and Nitrogen Washout. – J. Ophoff (BE) 
  WS7.3 - Relationships between Lung Clearance Index (LCI), patient reported symptoms and Health Related Quality of Life (HRQoL) in CF. – K. O'Neill (UK) 
  WS7.4 - Does Lung Clearance Index Predict Time to Pulmonary Exacerbation? – F. Vermeulen (BE) 
  WS7.5 - Lung function and structure in CF infants diagnosed through newborn screening (NBS). – L. Thia (UK) 
  WS7.6 - Effect of Ivacaftor on Lung Function in Subjects with CF Who Have the G551D-CFTR Mutation and Mild Lung Disease: a comparison of lung clearance index (LCI) vs. spirometry – J. Davies (UK) 
17:00-18:30  Workshop 8 - Making Sense of CFTR
  Moderators: C. Férec (FR) / C. Castellani (IT) 
  WS8.1 - The First 1,000 CFTR Genes Sequenced in the Mayo Clinic Clinical Molecular Genetics Laboratory. - W. Highsmith (US) 
  WS8.2 - Evaluation of Next Generation Sequencing as a Diagnostic Tool for CFTR Rare Mutation Screening – D. Beattie (UK) 
  WS8.3 - Co-implication of the 5’ and 3’ regions of CFTR exon 10 in its alternative splicing: prediction to pathology – R. Farhat (FR) 
  WS8.4 - Consequences of partial duplications of the human CFTR gene on CF diagnosis: Mutations or Ectopic Variations – V. Ladeveze (FR) 
  WS8.5 - Help for the Interpretation of Unclassified Variants: Example of the UMD-CFTR-France Locus Specific Database – C. Thèze (Fr) 
  WS8.6 - Decision algorithm and scoring method for the classification of variants of unknown clinical significance in the CFTR gene – C. Raynal (FR) 
  WS8.7 - Preimplantation genetic diagnosis for Cystic Fibrosis using multiplex fluorescent PCR – A. Girardet (FR) 
  WS8.8 - The diffusion processes of the CFTR mutations in Brittany (France) – N. Pellen (FR) 
  WS8.9 - Identification of High Frequency non-CFTR Genetic Risk Factors – J. LaRusch (US) 
  WS8.10 - Comparative Quantitative Proteomics of Wild-Type and CF Primary Nasal and Bronchial Epithelial Cells – F. Gisler (CH) 
17:00-18:30  Workshop 9 - Defending the Airways
  Moderators: C. O’ Kane (UK) / E. Reeves (IE) 
  WS9.1 - Clinical isolates of Prevotella histicola drive MMP-9 secretion by mononuclear cells – M. Jackson (UK) 
  WS9.2 - Abnormal Lipid Raft Structure as a Potential Cause for Impaired Neutrophil Activity in Cystic Fibrosis – S. Cox (IE) 
  WS9.3 - Contribution of the Th17 pathway in lung inflammatory response in F508del-CFTR mice – S. Noel (BE) 
  WS9.4 - A Th17- and Th2-skewed Cytokine Profile in the Lung of CF Patients Represents a Risk Factor for Infection with Pseudomonas Aeruginosa (PA) – K. Tiringer (AT) 
  WS9.5 - CF Epithelial Cells are a Source of Pulmonary Cathepsin S via Increased IRF-1 – S. Weldon (UK) 
  WS9.6 - A role for TLR9 in Pseudomonas aeruginosa-induced lung inflammation – F. Ben Mohamed (FR) 
  WS9.7 - Modulatory effects of Aspergillus colonization and ABPA on blood and sputum eosinophils and neutrophils in CF – Y. Gernez (US) 
  WS9.8 - Toll Like Receptor 4 is not targeted to the lysosome in Cystic Fibrosis airway epithelial cells – B. Schock (UK) 
  WS9.9 - The CFTR Potentiator Ivacaftor Corrects Defective Degranulation of Secondary and Tertiary Granules by Cystic Fibrosis Neutrophils – K. Pohl (IE) 
17:00-18:30  Workshop 10 - Barebones of Physiotherapy
  Moderators: I. Maguire (IE) / H. Parrott (UK) 
  WS10.1 - Evaluation of musculoskeletal and postural function in cystic fibrosis using a physiotherapy screening tool – B. Button (AU) 
  WS10.2 - Impact of Osteopathic Manipulative Treatment on Pain of Adult Patients with Cystic Fibrosis – a Pilot Randomized Study – D. Hubert (FR) 
  WS10.3 - Thoracic Kyphosis and Complications in Adult and Paediatric CF Patients– multi centre data collaboration. – C. Reilly (IE) 
  WS10.4 - Length of Hospital Stay and Changed Weekend Physiotherapy Cystic Fibrosis Service – F. Moran (AU) 
  WS10.5 - Comprehensive Exercise Training During Hospitalization for an Acute CF Exacerbation: A Randomized Controlled Trial – J. Lowman (US) 
  WS10.6 - Canadian National Airway Clearance Study: Positive Expiratory Pressure Mask versus High Frequency Chest Wall Oscillation –  J. Agnew (CA) 
17:00-18:30  Workshop 11 - Unravelling Virulence
  Moderators.: M. Prentice (IE) / N. Hoiby (DK)
  WS11.1 - Role of short chain fatty acids produced by anaerobic bacteria in Cystic Fibrosis – M. Murray (IE)
  WS11.2 - Novel LTTR plays a key role in biofilm formation and pathogenicity in P. aeruginosa – R. McCarthy (IE)
  WS11.3 - A role of pulmonary cytosolic phospholipase A2 in mouse mortality by Pseudomonas aeruginosa infection – Y. Wu (FR)
  WS11.4 - Host response to Pseudomonas aeruginosa adaptation during airway chronic infection – N. Lorè (IT)
  WS11.5 - Reversible Proline Hydroxylation in the Guanylate Cyclase SadC regulates alginate export in Pseudomonas aeruginosa – A. Schmidt (DE)
  WS11.6 - Environmental Burkholderia cenocepacia strains can disrupt epithelial integrity in bronchial epithelial cells in vitro and have a more profound effect on ZO-1 in CF cells. – S. McClean (IE)
  WS11.7 - Expression of the NF-?B inhibitor A20 is altered in the Cystic Fibrosis epithelium – B. Schock (UK)
  WS11.8 - Adaptation and survival of Burkholderia cenocepacia within the CF lung throughout the course of infection – J. Tyrrell (IE)
  WS11.9 - Bacterial cis-2-unsaturated fatty acids found in the cystic fibrosis airway play a role in bacterial interspecies signalling during polymicrobial infection of the CF lung – K. Twomey (IE)
  WS11.10 - Proteomic Analysis of the Chronically Infected CF Airways – S. Pattison (UK)
17:00-18:30  Workshop 12 - Emerging Dilemmas in CF Care
  Mod: C. Shortt (IE) / K. Colpaert (BE) 
  WS12.1 - The Prevalence of Substance Abuse in Cystic Fibrosis – S. Malhotra (CA) 
  WS12.2 - Outcomes of Patients With Cystic Fibrosis Admitted to an Intensive Care Unit – B. Markewitz (US) 
  WS12.3 - Educational needs for transplanted Cystic Fibrosis Patients – V. David (FR) 
  WS12.4 - Surviving But Stigmatised: Making Sense of Living with Burkholderia Cepacia – E. Smallman (UK) 
  WS12.5 - Fathers with Cystic Fibrosis in Italy: Who Are They? How Are They Doing? – B. Messore (IT) 
  WS12.6 - Social Challenges Facing Patients with CF on Their Path to Adulthood – S. Wanyama (BE) 
19:00-20:30

Johns Hopkins University School of Medicine Satellite Symposium - Programme

Johns Hopkins logo

Friday 8 June 
07:15-08:15  Round Tables
07:15-08:15  Abbott Satellite Symposium - Programme
Abbott logo
08:30-10:00  Symposium 13 - Allied Health Professionals and Nursing Research - The Next Step 
  Moderators: J. Bradley (UK) / S. Madge (UK)
  Identifying Funding Opportunities and Writing a Grant Proposal – M. Elkins (AU)
  How to Complete Regulatory Documents – T. Lee (UK) 
  Finding Collaborators, Working across Many Sites: Lessons from The Menopause Study – A.  Tsang (CA)  
  Setting up a Multi-National Trial: Lessons from TIDES – A. Quittner (US)
08:30-10:00  Symposium 14 - Basic Ion Transport Defects in CF 
  Moderators.: B. Harvey (IE) / U. Seidler (DE)
  Insights into the Pathogenesis of CF Lung Disease from CF Pigs – M. Welsh (US) 
  Regulation of ASL by Bioactive Lipids  – B. Harvey (IE) 
  Modulating transepithelial ion transport to restore the hydration of CF airways– O. Zegarra-Moran (IT) 
  Mechanisms of NHERF-Dependent Regulation of Ion transport  - H. De Jonge (NL)
08:30-10:00  Symposium 15 -Lipid Signaling – Bioactive Lipids
  Moderators: H. Verkade (NL) / Å. Nilsson (SE)
  Ceramide in cystic fibrosis –  E. Gulbins (DE)
  Modulators of sphingolipid metabolism reduce lung inflammation – C. Dechecchi  (IT)
  A role of PLA2 in the elimination of S. aureus from CF lung  - Y. Wu (FR) 
  New Lipidomic Approaches in CF - M. Ollero (FR)
08:30-10:00  Symposium 16 -Clinical Implications of Inflammation Remodelling
  Moderators: D. Hartl (DE) / N. Regamey (CH)
  Inflammation and Remodelling in Infants - F. Ratjen (CA)
  Neutrophils and Injury - D. Hartl (DE)
  Imaging Inflammation and Remodelling - N. Regamey (CH)
  Biomarkers of Inflammation and Injury - S. Sagel (US)
08:30-10:00 Symposium 17 - Managing Complex Infections in Advanced Lung Disease
  Moderators: T. Pressler (DK) / J. Foweraker (UK)  
  Managing Methicillin-resistant Staphylococcus aureus - Marianne Muhlebach (US) 
  Achromobacter – M. Skov (DK) 
  Burkholderia cepacia complex and Other Resistant Gram Negatives - P. Noone (US) 
  Managing Non Tuberculous Mycobacteria – C. Haworth (UK) 
08:30-10:00  Symposium 18 - Outcome Measures for Clinical Trials
  Moderators: H. Tiddens (NL) / N. Derichs (DE)
  Novel Outcomes - What Standards Must Be Met? - I. Eichler (EMA)
  Lung Clearance Index – S. Cunningham (UK)
  Chest Computed Tomography - H. Tiddens (NL)
  Diaries and Patient Reported Outcomes – C. Goss (US)
10:00-10:30  Coffee Break 
10:30-12:00  Symposium 19 - Assisted Reproductive Medicine for CF Patients: Partner Testing and Preimplantation Diagnositcs 
  Moderators:  A. Girardet (FR) / D. Barton (IE)
  Guidelines for Partner Testing – D. Barton (IE) 
  PGD: State of The Art and Future Developments  -  M. Derycke (BE) 
  Polar body analysis as an alternative PID tool – S. Rechitsky (US)
  Guidelines for Preimplantation Diagnostics – S. SenGupta (UK)
10:30-12:00  Symposium 20 - Rescue Strategies 
  Moderators: L. Galietta (IT) / P. Harrison (IE) 
  Overview of Proteins involved in Membrane Trafficking - P. Harrison (IE) 
  Target Identification – M. Amaral (PT) 
  3-Dimensional Structure of CFTR - I. Callebaut (FR) 
  Small Molecules to Correct Defective CFTR Function - D. Thomas (CA) 
10:30-12:00  Symposium 21 - The Clinical Microbiology Laboratory and CF Care 
  Moderators: K. Schaffer (IE) / H. Krogh Johansen (DK) 
  Optimal Sampling for CF Infection - P. McNally (IE) 
  Identification of Emerging Pathogens -  JM Rolain (FR) 
  Pseudomonas aeruginosa Bacteraemia during Acute Exacerbation- G. Döring (DE) 
  New Approaches to Antimicrobial Susceptibility Testing – J. Foweraker (UK) 
10:30-12:00  Symposium 22 - E-Health 
  Moderators:  G. Latchford (UK) / E. Hunstad (NO) 
  Cell Phone Intervention to Improve Adherence in Adolescents with CF -  K. Marciel (US) 
  Tele-Health Consultation in CF - D. Reid (AU) 
  ECORN-CF Evaluation of Its Impact – K. De Rijcke (BE) 
  Internet Interventions  -  C. Knaevelsrud (DE)  
10:30-12:00  Symposium 23 - Taking Care of the CF Patient after Lung Transplantation 
  Moderators: L. Dupont (BE) / K. Redmond (IE) 
  Which Patient Is Unsuitable for Lung Transplantation - P. Barry (IE) 
  Drug Interactions and Pharmacokinetics - C. Knoop (BE) 
  Microbiology of the Lung Allograft - A. Fisher (UK) 
  Long-term Outcome and Complications- L. Dupont (BE) 
10:30-12:00  Symposium 24 - Enhancing CFTR Functions - What's in the Pipeline? 
  Moderators: I. Fajac (FR) / J. Davies (UK) 
  Blocking Sodium Channels – M. Mall (DE) 
  Kick-Starting the Stop Mutations – M. Wilschanski (IL)  
  Correcting & Potentiating CFTR – J.P. Clancy (US) 
  Trial Design: How Long? What Age? What Do We Measure? - K. De Boeck (BE) 
12:00-15:00  Lunch 
12:30-14:00  Novartis Satellite Symposium - Programme
Novartis logo
14:00-15:00  Guided Poster Tours and Posters for Discussion 
14:00-15:00  ePoster Corner Sessions 
15:00-16:30   Workshop 13 - Keeping Bones Strong
  Moderators: D. Shimmin (UK) / A. Morton (UK)  
  WS13.1 - The effect of PPI usage on bone health in children with cystic fibrosis (CF) – M. Roddy (IE) 
  WS13.2 - Cystic fibrosis bone disease: is there a need for an earlier evaluation? – F. Majo (IT) 
  WS13.3 - Reduction in Prevalence of Osteoporosis and Osteopenia in Adult Patients Attending a Regional UK Centre: 2011 vs. 1999 – C. Etherington (UK) 
  WS13.4 - Vitamin D levels among CF adults compared to general adult population in Canada – M. Mailhot (CA) 
  WS13.5 - Effectiveness of a High-Dose Vitamin D Supplementation Regimen – M.  O'Driscoll (UK) 
  WS13.6 - A Treatment Algorithm for Vitamin D Deficiency – A. Ochota (UK) 
15:00-16:30   Workshop 14 - Early Stage Therapies
  Moderators: M. Mall (DE) / O. Zegarra-Moran (IT)
  WS14.1 - Ivacaftor Potentiates Mutant CFTR Forms Associated with Residual CFTR Function – F. Van Goor (US)
  WS14.2 - Efficient Delivery of the human CFTR gene to Pig lungs – J. Hu (CA)
  WS14.3 - Human Amniotic Mesenchymal Stem Cells can Partially Correct the Cystic Fibrosis Phenotype Upon Coculture with F508del Airway Epithelial Cells – A. Carbone (IT)
  WS14.4 - Correction of Both NBD1 Energetics and Domain Interface is Required to Restore ?F508 CFTR Folding and Function – W. Rabeh (UAE)
  WS14.5 – A Functional CFTR Assay Using Primary Cystic Fibrosis Intestinal Organoids – F. Dekkers (NL)  
  WS14.6 - Beta-adrenergic sweat secretion rate as accurate biomarker for CFTR function – T. Gonska (CA)
15:00-16:30   Workshop 15 - Sorting out the Salt
  Moderators M. Hug (DE) / V.Urbach (IE)
  WS15.1 - Volume Increase in Alveolar Type II Cells Following Fusion Dependent Activation of P2X4 Receptors on Lamellar Bodies – Linking Secretion and Fluid Transport in the Lung? – K. Thompson (DE)
  WS15.2 - Airway Surface Liquid layer height in Cystic Fibrosis Bronchial Epithelial cells is increased by Lipoxin A4 via an apical ATP release activating a P2Y receptor pathway – G. Higgins (IE)
  WS15.3 - Channel Activating Proteases (CAPS): Identification of Novel Targets for Correcting Sodium Channel Dysfunction in Cystic Fibrosis – J. Reihill (UK)
  WS15.4 - Study of the chloride channel ANO1 in cystic fibrosis context – M. Ruffin (FR)
  WS15.5 - Transcomplementation by a truncation mutant of CFTR, ?27-264 CFTR rescues both trafficking and chloride channel function of ?F508 CFTR – L. Cebotaru (US)
  WS15.6 - Upregulation of MicroRNA-148b in Cystic Fibrosis like Lung Disease of ?ENaC-overexpressing Mice – R. Agrawal (DE)
15:00-16:30   Workshop 16 - Exercise to Energise
  Moderators: L. Kent (UK) / W. Gruber (DE) 
  WS16.1 - Energy expenditure during a session of physiotherapy in CF patients. – F. Lessire (BE) 
  WS16.2 - The reliability of maximal cardiopulmonary exercise testing for young cystic fibrosis patients – C. Williams (UK) 
  WS16.3 - The 6-Minute Walk Test in the follow-up of CF Lung Transplant Recipient – C. Cazzarolli (IT) 
  WS16.4 - The Relationship Between Lung Function and Modified Shuttle Test Performance in Adult Patients with Cystic Fibrosis – W. Doeleman (NL) 
  WS16.5 - Airway Clearance Therapy and Exercise in Cystic Fibrosis: Patient´s Perceptions Versus Participation. – F. Kennedy (IE) 
  WS16.6  - Efficacy of an Educational Intervention of Physical Activity for Children and Adolescents with Cystic Fibrosis – P. Marostica (BR) 
  WS16.7 - Development of an Incremental Field Exercise Test for Children with Cystic Fibrosis. – S. Rand (UK) 
  WS16.8 - Habitual physical activity in adults with cystic fibrosis compared to controls – B. Button (AU) 
  WS16.9 - 12-Month Intensive Individualised Exercise Training Improves VO2Peak in a Group of Children With Low-Medium Initial Fitness Level – S. Ledger (UK) 
  WS16.10 - correlation between different tests to assess exercise capacity in patients with cystic fibrosis(CF) – M. Donà (IT) 
15:00-16:30   Workshop 17 - Understanding the Inflamed Airway
  Moderators: C. Taggart (UK) / D. Hartl (DE)
  WS17.1 - Modulation of inflammatory mediators associated with cystic fibrosis by alpha-1 antitrypsin. – D. Bergin (IE)
  WS17.2 - Anti-inflammatory therapy in a mouse model of P. aeruginosa lung infection leads to bacteraemia – G. Döring (DE)
  WS17.3 - Alteration of human macrophages functions in cystic fibrosis – K. Simonin-Le Jeune (FR)
  WS17.4 - Anti-pseudomonas IgY antibodies opsonize Pseudomonas aeruginosa, augmenting the phagocytosis activity of polymorph nuclear neutrophils. – K. Thomsen (DK)
  WS17.5 - Increased apoptosis and lack of invariant NKT cells in patients with cystic fibrosis leads to circulating antinuclear antibodies – G. Döring (DE)
  WS17.6 - Cystic Fibrosis Airway Epithelial Cells Interact With Dendritic Cells To Produce Immune Tolerance – M. Brodlie (UK)
  WS17.7 - Itraconazole up-regulates the Vitamin D receptor and reduces T-helper 2 responses in individuals with cystic fibrosis colonized with Aspergillus fumigatus. – C. Coughlan (IE)
  WS17.8 - Inhibition of leukotriene B4 signaling by alpha-1 antitrypsin: support for the use of aerosolized alpha-1 antitrypsin therapy in cystic fibrosis. – C. O' Dwyer (IE)
  WS17.9 - The B Lymphocyte Differentiation Factor, BAFF, is Expressed in the Lung of Cystic Fibrosis Patients and in a Mouse Model of Pseudomonas Aeruginosa Infection – G. Saint (UK)
  WS17.10 - Sputum Biomarkers and The Prediction of Clinical Outcomes in Patients with Cystic Fibrosis – T. Liou (US)
15:00-16:30   Workshop 18 - Old Bugs, New Challenges
  Moderators: M. Tunney (UK) / C. Gunaratnam (IE)
  WS18.1 - Failure of Eradication Therapy of Pseudomonas aeruginosa in Cystic Fibrosis: watch the nose – M. Berkhout (NL)
  WS18.2 - Persistent elevation of antibodies against Pseudomonas aeruginosa following successful eradication? – M. Griese (DE)
  WS18.3 - A Twenty-Five Year Outbreak of Pseudomonas aeruginosa: Identification of the Prairie Epidemic Strain (PES) – B. Glezerson (CA)
  WS18.4 - Heterogeneity of shared Pseudomonas aeruginosa (Pa) strains between Australian states and centres in cystic fibrosis (CF). – T. Kidd (AU)
  WS18.5 - MRSA in Cystic Fibrosis: potential for transmission within CF centres? – D. Gilpin (UK)
  WS18.6 - Outbreak of Burkholderia contaminans infection in children with cystic fibrosis: short term lung function and nutritional outcome – F. Renteria (AR)
16:30-17:00  Coffee Break 
17:00-18:30  Workshop 19 - Improving what we do
  Moderators: T. Havermans (BE) / G. Leen (IE)
  WS19.1 - Using Microsystems Methods to Improve Nutritional Outcomes in an Adult CF Center: A Quality Improvement (QI) Initiative – M. Ferrin (US)
  WS19.2 - Development and Application of Quality Improvement Questionnaire in Adults with Cystic Fibrosis. – B. Grogan (IE)
  WS19.3 - Transforming clinics to support adherence: an excercise in continuous quality improvement – Y. Locke (UK)
  WS19.4 - CF Quality Improvement Program: a Pilot Phase to experiment the US QIP Approach in France – G. Rault (FR)
  WS19.5 - Health Status in Individuals with Cystic Fibrosis Over the Period of Transition to Adult Services – A. Thorpe (UK)
  WS19.6 - The Frequent Flyer Programme: Results Of A 12-Month Quality Improvement Initiative Focused On Intensive Outpatient Physiotherapy And Dietetic Support – S. Ledger (UK)
17:00-18:30  Workshop 20 - Diversity and Richness: the CF Microbiome
  Moderators: P.Murphy (IE) / K. Bruce (UK)
  WS20.1 - Target minority bacterial population in Cystic Fibrosis lung microbiota – JM. Rolain (FR)
  WS20.2 - A Novel gyrB Sequence Cluster Approach for the Identification of Multiple CF Pathogens – D. Kenna (UK)
  WS20.3 - Use of Matrix-Assisted Laser Desorption Ionisation-Time of Flight (MALDI-TOF) Mass Spectrometry for Identification of Non-Fermentative Gram Negative Bacteria in Cystic Fibrosis and Non-CF Bronchiectasis – A. Lake (UK)
  WS20.4 - Real-time PCR (RT-PCR) provides a “window of opportunity”: optimal screening of patients with cystic fibrosis (CF) through an earlier detection of Pseudomonas aeruginosa (PA). – G. Héry-Arnaud (FR)
  WS20.5 - The Airway Microbiome in Children with Cystic Fibrosis – J. Renwick (IE)
  WS20.6 - Comparison of microbial composition in the lower airway of young children with and without cystic fibrosis using 16S rRNA gene pyrosequencing. - J. Legg (UK)
17:00-18:30  Workshop 21 - Eurovision Screening
  Mod: B. Linnane (IE) / J. Dankert-Roelse (NL)
  WS21.1 - Recruitment and Retention of Newborn Screened (NBS) Infants to an Observational Study with Invasive Outcome Measures. – J. Chudleigh (UK)
  WS21.2 - Newbornscreening for Cystic Fibrosis with an IRT-PAP-Protocol - J Hammermann (DE)
  WS21.3 - Cystic Fibrosis Newborn Screening protocols (IRT/IRT and IRT/DNA) comparison – Z. Kusova (RU)
  WS21.4 - Newborn screening for cystic fibrosis in Switzerland – Evaluation after one year – J. Barben (CH)
  WS21.5 - Newborn screening for cystic fibrosis - Polish four years’ experience with CFTR sequencing strategy – K. Wertheim-Tysarowska (PL)
  WS21.6 - 11 Years of Newborn Screening (NBS): The experience in Tuscany, Italy – T. Repetto (IT)
  WS21.7 - Newborn Screening for Cystic Fibrosis in Ontario, Canada: The First Three Years – S. Zelenietz (CA)
  WS21.8 - Assessment of the UK CF Newborn Screening (NBS) Programme; a protocol that uses a high cut-off for the first IRT measurement – K. Southern (UK)
  WS21.9 - Cascade testing in families of carrier newborns identified through CF newborn screening in western Brittany, France. – I. Duguépéroux (FR)
  WS21.10 - The Impact of a National Newborn Screening Programme on Sweat Testing Services – J. Harrington (UK)
17:00-18:30  Workshop 22 - Late Breaking Science
  Moderators: D. Sheppard (UK) / M. Mall (DE) 
  Review of the ECFS Basic Science conference 2012  –  L. Galietta (IT) 
  Results of the Phase 3 Study of Ataluren in Nonsense Mutation Cystic Fibrosis (nmCF) - M. Konstan (US)  
  WS6.1 - Efficacy of hypertonic saline in infants and young children: the ISIS study – F. Ratjen (CA) 
17:00-18:30  Workshop 23 - Issues in Clinical Care
  Moderators: S. Bell (AU) / S. Gartner (ES) 
  WS23.1 - Progression of lung disease within specific genotypes of patients with cystic fibrosis (CF) – which lung function parameter differentiates best? – R. Kraemer (CH) 
  WS23.2 - Chest X-ray Scores and Chest CT Scores Up To 5 Years Apart Are Highly Correlated – D. Sanders (US) 
  WS23.3 - Sputum Candida albicans is associated with radiological abnormalities in a cystic fibrosis cohort – T. McEnery (IE) 
  WS23.4 - High rhinovirus burden in lower airways of children with cystic fibrosis – N. Regamey (CH) 
  WS23.5 - Early recognition of CF related diabetes in children by the use of continuous glucose monitoring systems – R. Rayner (UK) 
  WS23.6 - Assessment of Renal Function in Cystic Fibrosis Patients by Estimated and Measured Glomerular Filtration Rate-A Cross-sectional Study – K. Jain (UK) 
17:00-18:30  Workshop 24 - Challenges to the CF Airway
  Moderators: T. Pressler (DK) / D. Hubert (FR)
  WS24.1 - Sinonasal Pathology in Adult Patients with Cystic Fibrosis – M. Berkhout (NL)
  WS24.2 - Extensive Sinus Surgery and Follow-up can Eradicate Pathogenic Bacterial Sinusitis in Patients with Cystic Fibrosis (CF) – K. Aanaes (DK)
  WS24.3 - Evaluation of the performance of sonic nebuliser to target maxillary sinuses. – S. Le Guellec (FR)
  WS24.4 - Impact Of Air Pollution On Cystic Fibrosis: A Case-crossover Analysis – P. Goeminne (BE)
  WS24.5 - Unresponsive Patients Benefit from Switching Intravenous Antibiotic Treatments for Pulmonary Exacerbation – D. VanDevanter (US)
  WS24.6 - Treatment of Pulmonary Infection with Mycobacterium Abscessus Complex in Adults with Cystic Fibrosis – U. Hill (UK)
19:00-20:30 

Forest Satellite Symposium - Programme 

 Forest logo

21:00  ECFS Party
Saturday 9 June 
09:00-10:30  Symposium 25 - Treating Fungal Disease in CF 
  Moderators: B. Plant (IE) / S. Bell (AU) 
  ABPA – R. Moss (US) 
  Aspergillus – G. McElvaney (IE) 
  Scedosporium – JP Bouchara (FR) 
  Other Fungal Pathogens – E. Tullis (CA) 
09:00-10:30   Symposium 26 - Genetic Epidemiology of CF Lung Disease 
  Moderators: A. Mehta (UK) / M. Stern (DE) 
  CFTR2 Genotype/Phenotype; Its Relevance to European Datasets – C. Castellani (IT) 
  Modifier Genes from Bedside to Bench – M. Drumm (US)
  Gene x Environment Interaction - M. Collaco (US)  
  Impact of Modifier Genes on Clinical Outcomes – H. Corvol (FR) 
09:00-10:30   Symposium 27 - Liver Disease and CF 
  Moderators: M. Wilschanski (IL) / M. Rowland (IE) 
  The possible role of bile acid derivatives in treatment of CF liver disease – L. Kazemi-Shirazi (AT) 
  Biomarkers in CF Liver Disease - K. Gaskin (AU) 
  Ursodeoxycholic Acid Treatment: Helpful or Harmful? - H. Verkade (NL) 
  Treatment of Chronic CF Liver Disease - B. Bourke (IE) 
09:00-10:30   Symposium 28 - Use of Technological Adjuncts for Airway Clearance 
  Moderators: I. Maguire (IE) / M. Elkins (AU) 
  Physiology of Mucociliary Clearance – M. Elkins (AU) 
  Positive Pressure for airway clearance – F. Moran (UK) 
  High Frequency Chest Wall Oscillation – M. McIlwaine (CA) 
  New Inhalation Techniques – D. Geller (US) 
09:00-10:30   Symposium 29 - Practical Issues in End of Life Care 
  Moderators:  V. Hall (UK) / S. Madge (UK)
  End of Life Care – What can we learn from other diseases – D. Fitzsimons (UK) 
  Psychological Issues – U. Smrekar (AT) 
  Patient Autonomy in Decision Making at End of Life -  U. Pypops (BE) 
  Models of Palliative Care – S. Bourke (UK) 
09:00-10:30   Symposium 30 - Exacerbations in CF: Optimising Outcomes 
  Moderators: C. Gallagher (IE) / P. Flume (US) 
  What Are CF Exacerbations ? Definition and Diagnosis - C. Gallagher (IE) 
  Pathogenesis and Immunobiology – A. Bush (UK) 
  Management of Exacerbations: What Works? – D. Bilton (UK) 
  How to Prevent Exacerbations? – D. Sanders  (US) 
10:30-11:00  Coffee Break 
11:00-12:30  Plenary 
  Inflammation and Infection - Lessons from the CF Pig Model - P. McCray (US) 
  Potentiating and Correcting CFTR - K. De Boeck (BE) 
  ECFS President's Address - S. Elborn (UK) 
12:30-13:00  Closing Ceremony